{"id":166778,"date":"2020-09-25T18:54:15","date_gmt":"2020-09-25T16:54:15","guid":{"rendered":"https:\/\/who.africa-newsroom.com\/press\/coronavirus-us35-billion-price-tag-to-end-the-acute-phase-of-the-pandemic?lang=en"},"modified":"2020-09-25T18:54:15","modified_gmt":"2020-09-25T16:54:15","slug":"coronavirus-us35-billion-price-tag-to-end-the-acute-phase-of-the-pandemic","status":"publish","type":"post","link":"https:\/\/www.myza.co.za\/press\/coronavirus-us35-billion-price-tag-to-end-the-acute-phase-of-the-pandemic\/","title":{"rendered":"Coronavirus: US$35 billion price tag to end the acute phase of the pandemic"},"content":{"rendered":"

\"World<\/a>
Download logo<\/a><\/p>\n

The ACT-Accelerator is the only global initiative offering a solution to speed up the end of the COVID-19 pandemic. Launched on 24 April 2020, it combines public and private sector expertise and institutions from around the world to accelerate the development, regulatory approval, scale-up, delivery and equitable allocation of COVID-19 tests, treatments and vaccines.<\/p>\n<\/p>\n

The ACT-Accelerator needs US$35 billion to meet the goal of developing new tools and producing and delivering 2 billion vaccine doses, 245 million treatments and 500 million diagnostic tests over the next year.<\/p>\n

With the largest portfolio of COVID-19 tools in the world, investing in the ACT-Accelerator increases the probability of being able to access the “winning candidate” and hedges the risk that countries that have already entered individual bilateral agreements end up with products that are not viable.<\/p>\n

The economic rationale for investment is clear:<\/p>\n